MeSH tree: D12.776.377.715.548
Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory studies prevented the virus from developing drug resistance—a persistent problem with current therapies ...
Allergy affects more than one billion people worldwide—and the number is rising. For many, it means mild symptoms such as itching and a runny nose. For others, it can develop into life-threatening reactions. Now, two new ...
Apr 11, 2026
0
14
Early results from preclinical studies and a clinical trial led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and Stanford Medicine suggest that combining targeted radiation therapy with an experimental ...
Mar 27, 2026
0
6
Vitamin D supplementation may help shape how the immune system responds to gut bacteria in people with inflammatory bowel disease (IBD), according to a Mayo Clinic-led study published in Cell Reports Medicine.
Mar 26, 2026
0
4011
A growing body of evidence suggests that long COVID (or post-COVID syndrome), a condition affecting more than 10% of people after a SARS-CoV-2 infection, may be driven by the immune system turning against the body. Now, new ...
Mar 24, 2026
0
50
Getting a tattoo can be a thrilling, albeit painful, experience. About one-third of Australians have a tattoo, with many getting inked as a rite of passage.
Mar 22, 2026
0
12
Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and ...
Mar 18, 2026
0
10
The World Federation of Societies of Biological Psychiatry (WFSBP) has reached consensus on candidate biomarkers for anorexia nervosa and published a statement. Lead author on the consensus statement, published in The World ...
Mar 13, 2026
0
8
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 inhibition offers an indirect ...
Mar 13, 2026
0
9
Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE).
Mar 12, 2026
0
6
